Using RAbMab Antibodies for Key Disease Targets in Parkinson’s Disease

Rabbit monoclonal antibodies are paving the way in the fight against Parkinson’s disease, targeting key disease targets and pushing research forward.

Abcam is collaborating with the Michael J. Fox Foundation to develop new tools for Parkinson’s disease research, such as rabbit monoclonal antibodies for leucine-rich repeat kinase (LRRK2), alpha-synuclein, DJ-1, RAB8A, and RAB10.

The Michael J. Fox Foundation (MJFF) was established with the goal of finding a cure for Parkinson’s disease and promote improved therapies for those living with the disease today.


Inherited Parkinson’s disease is most often due to the LRRK2 mutation. While this mutation has been well-studied, research has been hindered by the lack of high-quality LRRK2 antibodies available.

The MJFF-organized primary characterization of the LRRK2 molecule, in tandem with available data on rabbit monoclonal antibodies used for Parkinson’s disease research, has led to the emergence of three clones of rabbit monoclonal antibodies that have achieved the best performance parameters. These antibodies were thus selected for distribution via Abcam.

LRRK2 antibodies are critical in helping move Parkinson's research forward. The three unique clones chosen for initial release were identified based on several months of testing by our large network of PD researchers... we are excited that they [Abcam] will continue to help MJFF remove barriers to developing Parkinson's therapies. 

Dr. Mark Frasier, Vice President of Research Programs at MJFF.

LRRK2 Antibodies

Antibody name Clone ID Applications Species AbID
LRRK2 MJFF2 (c41-2) ICC/IF, IHC-FrFl, IHC-P, IP, WB Hu, Ms, Rt ab133474
LRRK2 MJFF3 (c69-6) ICC/IF, IHC-P, IP, WB Hu, Ms, Rt ab133475
LRRK2 MJFF4 (c81-8) ICC/IF, IHC-P, IP, WB Hu, Ms, Rt ab133476
LRRK2 MJFF5 (68-7) WB Hu, Ms ab181386
LRRK2 UDD3 30(12) ICC/IF, IHC-P, WB Hu, Ms ab133518
LRRK2 (phospho S910) UDD1 15(3) WB Hu ab133449
LRRK2 (phospho S935) UDD2 10(12) ICC/IF, WB Hu, Ms ab133450
LRRK2 (phospho S955) MJF-R11 (75-1) WB Hu, Ms ab169521
LRRK2 (phospho S973) MJF-R12 (37-1) WB Hu ab181364
LRRK2 (phospho T1410) MJFR4-25-5 WB Hu, Ms, Rt ab140107
LRRK2 (phospho T1491) MJFR5-88-3 WB Hu ab140106
LRRK2 (phospho T1503) MJF-R6 (227-1a) WB Hu ab154423
LRRK2 (phospho S1292) MJFR-19-7-8 WB Hu ab203181
LRRK2 (phospho T2483) MJF-R8 (21-2e) WB Hu ab156577



The first gene to be linked to Parkinson’s disease was alpha-synuclein, and is still considered the most promising link to Parkinson’s pathogenesis. Alpha-synuclein is found in Lewy bodies, of which it forms a large part. These bodies are characteristically found in the brains of individuals affected by Parkinson’s disease.

Synuclein Antibodies

Antibody name Clone ID Applications Species AbID
Alpha-synuclein MJFR1 ELISA, Flow Cyt, ICC/IF, IHC-P, IP, WB Hu, Drosophila melanogaster ab138501
Alpha-synuclein (phospho S129) MJF-R13 (8-8) WB Hu ab168381
Alpha synuclein filament - conformation specific MJFR-14-6-4-2 ICC/IF, IHC-P, dot blot Hu, Ms, Rt ab209538



DJ-1 or PARK7 is considered to act as a sensor that picks up the presence of oxidative stress within cells. This molecule has been investigated to detect changes that result from Parkinson’s pathogenesis, including protein oxidation.

DJ-1 Antibody

Antibody name Clone ID Application Species AbID
DJ1 (PARK7) MJF-R16 (66-5) WB Hu ab169520


Rab8A and Rab10

There are some specific Rabs, or Rab GTPases, that can alter the activity level of alpha-synuclein. When these are not working properly, the impaired enzyme causes inherited early-onset Parkinson’s disease. Rab8 and Rab10 specifically help in trafficking glucose transporter type 4 (GLUT4) to the plasma membrane.

Rab Antibodies

Antibody name Clone ID Application Species AbID
Anti-RAB8A (phospho T72) [MJF-R20] WB, Dot blot Mo, Hu ab230260
Anti-RAB10 (phospho T73) [MJF-R21] WB, Dot blot Mo, Hu ab230261


About Abcam

Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.

Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.

Sponsored Content Policy: publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 13, 2019 at 9:10 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Abcam. (2019, June 13). Using RAbMab Antibodies for Key Disease Targets in Parkinson’s Disease. News-Medical. Retrieved on November 13, 2019 from

  • MLA

    Abcam. "Using RAbMab Antibodies for Key Disease Targets in Parkinson’s Disease". News-Medical. 13 November 2019. <>.

  • Chicago

    Abcam. "Using RAbMab Antibodies for Key Disease Targets in Parkinson’s Disease". News-Medical. (accessed November 13, 2019).

  • Harvard

    Abcam. 2019. Using RAbMab Antibodies for Key Disease Targets in Parkinson’s Disease. News-Medical, viewed 13 November 2019,

Other White Papers by this Supplier